Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer by Lu, Ming et al.
Hydrophobic Proteome Analysis of Triple Negative
and Hormone-Receptor-Positive-Her2-Negative Breast
Cancer by Mass Spectrometer
Ming Lu & Stephen A. Whelan & Jianbo He &
Romaine E. Saxton & Kym F. Faull &
Julian P. Whitelegge & Helena R. Chang
Published online: 7 September 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Introduction It is widely believed that discovery of specific,
sensitive, and reliable tumor biomarkers can improve the
treatment ofcancer.Currently,therearenoobvioustargets that
can be used in treating triple-negative breast cancer (TNBC).
Methods To better understand TNBC and find potential
biomarkers for targeted treatment, we combined a novel
hydrophobic fractionation protocol with mass spectrometry
LTQ-orbitrap to explore and compare the hydrophobic sub-
proteome of TNBC with another subtype of breast cancer,
hormone-receptor-positive-Her2-negative breast cancer
(non-TNBC).
Results Hydrophobic sub-proteome of breast cancer is rich in
membraneproteins.Hundredsofproteinswithvariousdefined
key cellular functions were identified from TNBC and non-
TNBC tumors. In this study, protein profiles of TNBC and
non-TNBC were systematically examined, compared, and
validated. We have found that nine keratins are down-
regulated and several heat shock proteins are up-regulated in
TNBC tissues. Our study may provide insights of molecules
that are responsible for the aggressiveness of TNBC.
Conclusion The initial results obtained using a combination
of hydrophobic fractionation and nano-LC mass spectrometry
analysisoftheseproteinsappearpromisinginthediscoveryof
potential cancer biomarkers and bio-signatures. When suffi-
ciently refined, this approach may prove useful in improving
breast cancer treatment.
Keywords Hydrophobic fractionation .Cancer biomarker.
Mass spectrometry.Triple-negative breast cancer.
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Abbreviations
ER Estrogen receptors
Her2 Human epidermal growth factor receptor 2
MHC Major histocompatibility complex
PR Progesterone receptors
TNBC Triple-negative breast cancer
Introduction
Breast cancer is the most common cancer in women, the
leading cause of death among young women aged 15–54,
and the second most common cause of cancer death in
American women [1]. Breast cancer is heterogeneous
molecularly, histologically, and clinically. As a result,
different types of breast cancer require special treatment
considerations. Chemical ligands such as hormones, when
bound to receptors, lead to a chain of changes in the cell.
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DOI 10.1007/s12014-010-9052-1Various receptors can be found on the cell surface, in the
cytoplasm, and in the nucleus, which determine the
biology and clinical behaviors of different types of breast
cancer. In breast cancer, estrogen receptor (ER), proges-
terone receptor (PR), and human epidermal growth factor
receptor 2 (Her2/neu) are the three biomarkers used
clinically to guide treatment. Breast cancer with negative
expression of the three biomarkers is known as triple-
negative breast cancer (TNBC). TNBC accounts for
approximately 15% of all invasive breast cancers [2, 3].
Recent gene analysis studies suggest that TNBC arises from
basal cells of the mammary epithelium [4–7]. TNBCs occur
more frequently in African-American women, young
women, and women with the BRCA1 mutations [3, 8, 9].
TNBC represents an aggressive type of breast cancer with
early relapse and poor survival rate [10]. Unfortunately,
chemotherapy remains the only available systemic treat-
ment, as there have been no effective target therapies
developed for TNBC.
Hormone receptor-positive Her2-negative breast cancer
represents the other end of the disease spectrum. Genomic
analysis classified them as luminal type A breast cancer
[11–13], which not only carry a better prognosis but are
also extremely susceptible to hormone therapy.
In this study, we compared the hydrophobic sub-
proteome of the two types of breast cancer: TNBC and
ER+PR+Her2− breast cancer. We wish to identify the
differentially expressed hydrophobic sub-proteome of
TNBC, which may distinguish it from the ER+PR+Her2−
breast cancer and provide further molecular insights of its
aggressive biology.
Proteomics has been employed recently to identify new
disease-related biomarkers for cancer diagnosis and develop-
ment of targeted treatment [14–19]. Since tumor/cancer
specimens are rich in cancer-related proteins and are directly
relevant to human disease, they were selected to study the
bio-signature of breast cancer.
A common strategy used in proteomics research is to
enrich a target set of proteins in order to identify the lower
abundance proteins that are important in cancer biology.
Many fractionation methods have been explored, including
isolation/enrichment of the membrane sub-proteome, such
as membrane glycoproteins [17], which may serve as a key
area to discover therapeutic and diagnostic targets. In this
study, we focused on membrane proteins as it accounts for
approximately one third of all open reading frames of
sequenced human genomes encoding the polytopic trans-
membrane proteins [20, 21]. Despite their critical biological
significance, membrane proteins remain under-studied due
to their poor solubility, making separation and mass
analysis difficult [22, 23]. Previously,our data demonstrated
that more membrane proteins were found in the hydrophobic
fraction of the tumor cells than the conventional membrane
proteins prepared by the centrifugation method [19]. White-
legge et al. [24–28] have also shown that not only cell
membrane proteins with a variety of functions, but also
sub-cellular organelle membrane proteins and acylated non-
membrane proteins were recovered in the hydrophobic sub-
proteome. We therefore chose membrane proteins enriched
by hydrophobic fractionation method to study a panel of 20
breast cancer samples.
Hydrophobicity is a common feature of many cellular
proteins, especially those residing within or associated with
lipid bi-layer membranes. Since membrane proteins play
critical roles within cells and endow cancer cells with many
of their unique properties, a strategy that enriches this class
of proteins may prove to be useful. While integral
membrane proteins can be predicted from their primary
sequences, association of other globular proteins with
membranes can be challenging if not impossible to predict.
Choice of hydrophobicity as a property for enrichment is
novel and offers the chance of finding “biomarker events”
that result in gain or loss of membrane association. In this
study, hydrophobic sub-proteome of breast cancer was
analyzed by combining LTQ-Orbitrap mass spectrometry
with several computational methods to identify a cohort of
moderate abundance proteins including several candidate
biomarkers related to malignancy.
Material and Methods
Human Samples
Breast specimens were collected prospectively from partici-
pants of an IRB-approved clinical study for discovery of cancer
biomarkers. Breast tissue was collected immediately after
needle biopsy or surgical removal according to the standard
operating procedures established for tissue and bio-specimen
collection. The collected specimen was delivered on ice to the
Tissue Bank, where it was divided into three parts: one in OCT
embedding medium for frozen tissue specimens (Tissue-Tekâ)
and two directly frozen in liquid nitrogen. All specimens were
stored frozen at −80°C.
Ten cases of each of the TNBC and ER+PR+Her2−
(non-TNBC) breast cancer tissues were compared. The
clinical histo-pathological information of the 20 cases is
summarized in Table 1.
Protein Extraction of Tumor Tissues
After removing the visible fat, breast tumors were rinsed in
cold PBS and homogenized in cold lysing buffer (150 mM
NaCl, 50 mM Tris–C l ,2m ME D T A ,1m Ms o d i u m
orthovanadate, containing 1% Triton X-100). The homoge-
nizer was immersed in slushy ice during 30 slow passes. The
94 Clin Proteom (2010) 6:93–103homogenate of each specimen was centrifuged at 12,000×g
for 10 min at 4°C to remove debris. Supernatants were
collected at 4°C, and protein concentration of each sample
was determined by Bradford assays before being frozen in
liquid nitrogen for storage at −80°C.
Hydrophobic Fractionation
We have successfully developed a hydrophobic fraction-
ation method to enrich membrane proteins [19]. We have
compared three different methods to enrich membrane
hydrophobic proteins by (1) traditional centrifugation
method, (2) hydrophobic column, (3) disposable spin
cartridge. We found the hydrophobic column identified
many more membrane proteins than the traditional centri-
fugation method. However, the hydrophobic column suf-
fered from a serious pressure build-up problem, which
limited its use in handling multiple samples. The findings
led to the development of disposable spin cartridge packed
with beads of polystyrene-divinylbenzene polymers, which
are the same as those used for commercially made
hydrophobic column. The beads were packed into a
single-use disposable spin cartridge to the same volume as
the hydrophobic column. The proteins identified by the
hydrophobic column and the disposable spin cartridge
showed an overlap greater than 95%. The disposable spin
cartridge has become the method of choice for hydrophobic
fractionation in our laboratory because of its proven
functionality, no pressure- build up, low cost, and zero
sample-to-sample cross contamination.
Briefly, each cartridge was activated with two sequential
methanol rinses, followed by washing with three sequential
rinses of water/acetonitrile/TFA (95/5/0.1, all by vol.). Speci-
mens of 1-mg cell lysates were loaded into the cartridges. The
cartridgeswerespunfor1minat110×g to remove the soluble
proteins, salts, and polar solutes such as DNA with five
sequential barrel washes using the following solvents:
1. Water/acetonitrile/isopropanol/TFA (90/05/05/0.1, all
by vol.)
2. Water/acetonitrile/isopropanol/TFA (70/15/15/0.1, all
by vol.)
3. Water/acetonitrile/isopropanol/TFA (50/25/25/0.1, all
by vol.)
4. Water/acetonitrile/isopropanol/TFA (30/35/35/0.1, all
by vol.)
5. Water/acetonitrile/isopropanol/TFA (10/45/45/0.1, all
by vol.)
The retained hydrophobic proteins were eluted with 1 mL
88%formicacidfollowedby2mLchloroform/methanol/H2O
(4/4/1, v/v, freshly prepared daily). Samples were collected
and dried in a vacuum concentrator and stored at −20°C.
Case no. Age Ethnicity Clinical stage ER/PR/Her2
1 61 White T3N0 (−/−/−) TNBC
2 45 Hispanic T3N0 (−/−/−) TNBC
3 55 Hispanic T3N0 (−/−/−) TNBC
4 54 Hispanic T3N0 (−/−/−) TNBC
5 40 Asian T3N1 (−/−/−) TNBC
6 44 White T3N1 (−/−/−) TNBC
7 84 Asian T4N0 (−/−/−) TNBC
8 38 White T2N0 (−/−/−) TNBC
9 52 White T2N0 (−/−/−) TNBC
10 52 White T2N0 (−/−/−) TNBC
Age average 52.5
1 57 Black T3N1 (+/+/−) non-TNBC
2 45 White T3N0 (+/+/−) non-TNBC
3 65 White T3N3 (+/+/−) non-TNBC
4 49 White T4N2 (+/+/−) non-TNBC
5 39 Hispanic T4N1 (+/+/−) non-TNBC
6 48 White T3N0 (+/+/−) non-TNBC
7 62 White T3N0 (+/+/−) non-TNBC
8 48 White T2N0 (+/+/−) non-TNBC
9 43 Asian T2N0 (+/+/−) non-TNBC
10 60 White T3N1 (+/+/−) non-TNBC
Age average 51.6
Table 1 Clinical characteristics
and pathological features of
tumors used in this study
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for LC/MS/MS
The dried samples were dissolved in freshly prepared
guanidine HCl (6 M, 20 μl) containing 10 mM DTT and
0.2% RapiGest (Waters, Milford, MA, USA), vortexed, and
incubated at 37°C for 1 h. Additional guanidine HCL (6 M,
2 μl) containing 300 mM iodoacetamide was added, mixed,
and incubated at 37°C for 1 h. The sample was digested by
trypsin (sequencing grade, Promega) in solution containing
1.6 ml 0.5 M ammonium bicarbonate and incubated for 4 h
at 37°C. Reverse phase C18 cartridges (AccuBond II
ODSC18) were used and the manufacturer's protocol was
followed to remove salt from the samples.
LC/MS/MS Analysis and Peptide Data Analysis
LC/MS/MS and data analysis were modified from Whelan
et al. [17]. Briefly, samples were redissolved in Buffer A
(H2O/acetonitrile/formic acid, 98.9/1/0.1, typically 50 μL),
separated by nanospray LC (Eskigent Technologies, Dublin,
CA, USA), and analyzed using online tandem mass
spectrometry (LTQ-Orbitrap, Thermo Fisher). Aliquots
were injected (10 μL) onto a reverse phase column (New
Objective C18, 15 cm, 75 μM diameter, 5 μm particle size
equilibrated in Buffer A) and eluted (300 nL/min) with an
increasing concentration of Buffer B (acetonitrile/water/
formic acid, 98.9/1/0.1; min 0/5, 10/10, 112/40, 130/60,
135/90, 140/90). The effluent from the column was passed
directly into an integrated nanospray emitter tip connected
to the LTQ-Orbitrap mass spectrometer. Eluted peptides
were analyzed by MS and data-dependent MS/MS acqui-
sition (collision-induced dissociation (CID)), previously
optimized for samples, selecting the seven most abundant
precursor ions for MS/MS with a dynamic exclusion
duration of 15.0 s.
Biowork software searchers were conducted using a human
trypsin cleavage indexed peptide database, with variable
modifications of carboxyamidomethylation (57.02146) and
methionine oxidation (15.99492). Scaffold data analysis
(Proteome Software, Version 2.2.03) was conducted using
Bioworks search file results with a high stringency filter with a
99% minimum protein ID probability, a minimum number of
two unique peptides for each protein identified, and with a
minimum peptide ID probability of 95%. Scaffold uses X!
Tandem [29], ProteinProphet computer algorithms [30], and
PeptideProphet [31] to verify peptide identifications derived
from MS/MS sequencing resul t s .S c a f f o l di sa l s ou s e dt o
quantitate spectral counts by normalizing MS/MS data between
samples. Each sample analyzed was a combination of three
replicateexperimentsandwasnormalizedbyaveragingspectral
counts for all samples, multiplying spectral counts in each
sample by the average and then dividing by each sample's sum.
Western Blotting Analysis
Twenty micrograms of protein was separated by a 12% SDS-
PAGE gel and transferred to a nitrocellulose membrane by
electrophoretic blotting. The membrane was blocked with 5%
nonfat dry milk in TBS-0.1% Tween 20 and then incubated
with primary antibody for 1 h. The blots were then washed 10
Fig. 1 Many hydrophobic proteins were found to be shared between
TNBC and ER+PR+Her2− breast cancers (non-TNBC). Unique proteins
were also found to be associated with either TNBC or ER+PR+Her2−
breast cancers. The pool of the unique proteins may include disease-
related biomarkers, and may potentially be used as therapy targets
Sample (1mg) Proteins identified Sample (1mg) Proteins identified
TNBC #1 130 Non-TNBC #1 159
TNBC #2 143 Non-TNBC #2 169
TNBC #3 110 Non-TNBC #3 127
TNBC #4 94 Non-TNBC #4 158
TNBC #5 60 Non-TNBC #5 177
TNBC #6 196 Non-TNBC #6 116
TNBC #7 154 Non-TNBC #7 122
TNBC #8 198 Non-TNBC #8 196
TNBC #9 185 Non-TNBC #9 178
TNBC #10 205 Non-TNBC #10 118
Table 2 Number of protein in
hydrophobic fraction of 1-mg
tissue lysates identified by
LTQ-Orbitrap
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horseradish peroxidase-conjugated secondary antibody, and
then washed in TBS-Tween 20 as before. The membranes were
then developed using the Supersignal West Pico Chemilumi-
nescent Western blotting detection system according to the
instructions of the manufacturer (Pierce, Arlington Heights, IL,
USA). Primary antibodies of keratin 19 and heat shock proteins
were purchased from Dako (Carpinteria, CA, USA) and Santa
Cruz Biotechnology (Santa Cruz, CA, USA), respectively.
Both antibodies were diluted 1:1,000 in Western blot analysis.
Results
1. Hydrophobic column chromatography combined with
the LTQ-Orbitrap MS/MS analysis detected hundreds
of proteins from human cancer tissue specimens.
The novel hydrophobic fractionation system effec-
tively enriched hydrophobic proteins of cancer tissues.
Combined with the LTQ-Orbitrap, hundreds of proteins
were identified in each sample. The significant number
of proteins identified provided a meaningful analysis of
disease-related biomarkers. Table 2 lists the number of
hydrophobic proteins identified by the LTQ-Orbitrap in
1 mg of each of the 20 samples.
2. Many shared and unique proteins were detected in
TNBC and non-TNBC specimen.
We compared hydrophobic proteins between 10 cases
ofTNBCandnon-TNBCspecimens(Fig.1 and Tables 3
and 4). As expected, many proteins were found to be
shared by TNBC and non-TNBC specimens. However,
a significant number of unique proteins were found to
be associated with either TNBC or non-TNBC speci-
mens. When confirmed, some proteins unique to TNBC
Identified proteins Accession number Molecular weight (kDa)
Keratin 18 gi|4557888 48
Perilipin gi|8134637 56
Galectin 3 binding protein gi|5031863 65
Zinc-alpha-2-glycoprotein gi|141596 (+1) 34
Collagen, type VI, alpha 1 gi|87196339 109
Creatine kinase gi|21536286 43
Prostatic binding protein gi|4505621 (+1) 21
Vesicle amine transport protein 1 gi|18379349 42
Chain A, cellular retinoic acid binding protein-type Ii gi|157830381 (+2) 16
Chain A, N-acetyltransferase 1 F125s mutant gi|119390179 (+2) 34
Sodium/hydrogen exchanger regulatory factor 1 gi|4759140 39
FK506 binding protein 52 gi|4503729 (+1) 52
Glycerol-3-phosphate dehydrogenase 1 (soluble) gi|33695088 38
Epiplakin 1 gi|13876386 553
Methylcrotonoyl-coenzyme A carboxylase 2 (beta) gi|11545863 61
Keratin 5 gi|119395754 62
Chain A, glutamate dehydrogenase-Apo form gi|20151189 (+3) 56
Phosphofructokinase gi|48762920 85
Chain A, carboxylesterase gi|114793717 (+1) 60
Table 4 Unique proteins
detected exclusively in the 10
ER+PR+Her2− breast cancer
cases
Identified proteins Accession number Molecular weight (kDa)
Cytoskeleton-associated protein 4 gi|19920317 66
HLA class II histocompatibility antigen, DR alpha chain gi|122206 (+5) 29
3′-phosphoadenosine 5′-phosphosulfate synthase 1 gi|46094058 (+1) 71
HLA class I histocompatibility antigen, A-23 alpha chain gi|231359 41
Transforming growth factor, beta-induced gi|4507467 75
Tapasin isoform 7 gi|114606885 48
Ribosome-binding protein 1 gi|23822112 152
UTP-glucose-1-phosphate uridylyltransferase gi|2136353 (+1) 57
Chain A, C-terminal Atpase domain of human Tap1 gi|15988434 (+1) 28
Table 3 Unique proteins
detected exclusively in 10
TNBC cases
Clin Proteom (2010) 6:93–103 97may represent valuable biomarkers for developing
diagnostics or targeted therapy.
HLA class II histocompatibility antigen DR alpha
and HLA class I histocompatibility antigen A-23 alpha
are trans-membrane proteins expressed on lympho-
cytes. More HLA histocompatibility antigens are found
in TNBC, indicating a significant presence of lympho-
cytic infiltration in TNBC specimens, which is a useful
histological feature of the TNBC.
3. Differentially expressed proteins by TNBC compared
with non-TNBC tissues.
Semi-quantitative analysis of TNBCs vs. non-TNBCs
by Scaffold 2.2.03 software showed that numerous
proteins were up-regulated (≥2.0-fold) or down-
regulated (≤0.5-fold) in the two types of breast cancer.
A list of proteins that up-regulated (≥2.0-fold changes,
Table 5) and down-regulated (≤0.5-fold changes,
Table 6) in TNBC was reported. Our data suggest that
these proteins may represent bio-signature of TNBC,
which may distinguish TNBC from ER+PR+Her2−
breast cancers.
4. Data validation by Western blotting analysis.
To confirm the findings observed from mass
spectrometry study, we have selectively validated the
MS-identified hydrophobic proteins by Western blot
(Fig. 2 and data not shown) and found that the higher the
spectrumcountsoftheproteinwere,themorelikelyitwas
that the proteins were identified by both methods. In most
cases, the expression levels of each protein detected by
Western blot were consistent with the finding of mass
spectrometry analysis. The strategy of combing different
fractionation methods and LC/MS/MS is useful in the
discovery of novel disease-related proteins.
5. Keratins were down-regulated in TNBC.
The keratins have an extraordinary wide presence
with 54 functional keratin genes reported in humans, 37
Table 5 Proteins over-expressed by TNBC (≥2-fold of up-regulation) when compared with ER+PR+Her2− (non-TNBC) cases
Proteins over-expressed in TNBC Accession no. Molecular
weight (kDA)
Fold of TNBC/non-TNBC Average detected
spectra of TNBC ± SE
Serine (or cysteine) proteinase inhibitor,
clade H, member 1
gi|32454741 46 4.7 11.3±6.4
Filamin A, alpha isoform 2 gi|160420317 281 4.5 36.1±12.9
Mitochondrial ATP synthase beta subunit gi|32189394 57 3.7 31.6±11.1
Heat shock protein 90 kDa beta, member 1 gi|4507677 92 3.3 30.1±8.9
Tropomyosin 4 isoform 2 gi|4507651 29 3.2 16.8±6.6
Tropomyosin 3 gi|58652133 33 3.1 1.1±0.5
ATP synthase, alpha subunit gi|4757810 60 2.9 24.8±6.6
Heat shock 70 kDa protein 5 gi|16507237 72 2.9 54.4±18.2
Three-dimensional structure
of a transglutaminase
gi|1127268 (+4) 83 2.8 6.2±2.0
High-mobility group box 1 gi|4504425 25 2.7 7.8±2.6
Moesin gi|4505257 68 2.7 6.6±2.8
Thymidine phosphorylase gi|118138578 (+1) 50 2.5 14.4±5.6
Enolase 1 gi|4503571 47 2.5 53.5±14.0
Fascin 1 gi|4507115 55 2.3 4.2±2.3
Fibrinogen, beta chain gi|70906435 56 2.3 6.0±3.8
Ribophorin I precursor gi|4506675 69 2.3 5.5±1.9
Tryptophanyl-tRNA synthetase isoform a gi|47419914 53 2.2 6.0±4.2
Cytoplasmic domain of erythrocyte
band-3 protein
gi|14277739 (+1) 43 2.1 6.1±2.7
Vimentin gi|62414289 54 2.1 32.4±9.6
Annexin I gi|4502101 39 2.1 25.7±11.5
Vitronectin gi|88853069 54 2.1 4.4±1.8
Lamin A/C isoform 1 gi|27436946 74 2 3.1±2.2
Annexin A2 isoform 2 gi|4757756 39 2 75.6±20.8
Collagen, type XII, alpha 1 long isoform gi|93141047 333 2 2.9±2.9
Vitamin D-binding protein I gi|21730554 (+2) 42 2 36.9±6.7
Porin 31HM gi|238427 (+1) 31 2 63.7±1.5
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according to their isoelectric points; type I is acidic and
type II is basic or neutral. Keratins are incorporated into
filaments by heteropolymeric pair formation of type I
and type II (1:1) molecules [32–34]. Keratins are not
only important for the mechanical stability and integrity
of epithelial cells and tissues [32]. Moreover, some
keratins also have regulatory functions and are involved
in intracellular signaling pathways, e.g., protection
from stress, wound healing, and apoptosis [32].
Mass spectrometric analysis of the hydrophobic
sub-proteome showed nine different epithelial kera-
tins (Table 7), all of which are over-expressed in the
ER+PR+Her2− breast cancer than the TNBC. This
finding has been confirmed by Western blot analysis with
keratin 19 expression in 14 breast cancer cases (Fig. 2).
6. Heat shock proteins were up-regulated in TNBC.
Heat shock proteins (Hsp90, Hsp70) are chaperones
that assist the proteins in their folding, stability, assembly
into multi-protein complexes, and transportation across
cellularmembranes.Theexpressionofheatshockproteins
is highly inducible by a wide variety of physiological and
environmental stresses [35]. Heat shock proteins have
cyto-protective functions by anti-apoptosis to promote
the survival of stressed cells. In TNBC cancer tissues,
Hsp70 and Hsp90 were found to be expressed consis-
tently at higher level than that of ER+PR+Her2 breast
cancer (Table 8). The results have been confirmed by
Western blot analysis (data not shown).
Discussion
In this study, we have investigated the differences of
hydrophobic sub-proteomes between two subtypes of breast
cancers (TNBC vs. ER+PR+Her2−). Mass spectrometry
(LC/MS/MS) techniques were used to compare the protein
Fig. 2 Mass data of keratin 19 expression in 14 breast cancer cases
are consistent with Western blot analysis
Table 6 Selected proteins down-regulated (≤0.5-fold) in triple-negative breast cancer (TNBC) tumor when compared with ER+PR+Her2− (non-
TNBC) tumor specimens (keratin data are listed in Table 7)
Proteins down-regulated in TNBC Accession no. Molecular
weight (kDa)
Fold of TNBC/non-TNBC Average detected
spectra of TNBC ± SE
Fatty acid synthase gi|67476453 273 0.08 1.0±0.7
Collagen alpha-3(VI) chain gi|5921193 344 0.2 5.8±1.9
Amine oxidase, copper containing 3 gi|4502119 (+1) 85 0.3 1.1±0.5
UDP-glucose dehydrogenase gi|4507813 55 0.4 0.1±0.1
Collagen, type XIV, alpha 1 gi|55743096 194 0.4 13.6±3.7
Triosephosphate isomerase 1 isoform 1 gi|4507645 (+2) 27 0.5 6.5±1.9
Periostin, osteoblast specific factor isoform 1 gi|209862907 93 0.5 7.4±2.8
Transketolase isoform 1 gi|4507521 68 0.5 9.2±4.3
Heat shock protein beta-1 gi|4504517 23 0.5 1.0±0.6
Lumican precursor gi|4505047 38 0.5 5.8±2.4
Plasma membrane associated protein, S3-12 gi|122937195 134 0.5 0.5±0.4
Osteoglycin gi|7661704 34 0.5 0.5±0.3
Immunoglobulin J chain gi|400044 16 0.5 0.4±0.2
Chain A, the intact and cleaved human
antithrombin Iii complex
gi|999513 49 0.5 3.7±2.4
CD36 antigen gi|48375176 53 0.5 0.5±0.5
Zinc-alpha-2-glycoprotein gi|141596 (+1) 34 0.5 0.1±0.1
Perilipin gi|8134637 60 0.5 0.1±0.1
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the comparison groups. We also report several candidate
proteins that may be involved in the aggressive manifesta-
tion of TNBC.
An interesting finding of this study was to discover that
all nine keratins found in breast cancers were down-
regulated in all 10 TNBC cases when compared with the
10 ER+PR+Her2− breast cancer cases. Keratins (previously
called cytokeratins) are filament-forming proteins and are
essential for normal tissue structure and function [36]. A
major function of epithelial keratins is to provide the
mechanical stability and integrity of epithelial cells and
tissues [32], as well as the mechanical support to epithelial
cell sheets [37]. The biological meaning and mechanism of
reduced keratins in TNBC has not been previously
investigated. Hypothetically, however, less keratin may
indicate that TNBC cells are less “stiff” and more “flexible”
in changing shapes to facilitate cellular movement, trans-
portation, and migration for its invasive nature and early
metastasis. It has been reported that metastatic cancer cells
are 70% softer than non-metastatic cells using nanome-
chanical analysis [38]. Down-regulated expression of
keratins in TNBC was also observed by another study in
our laboratory (Whelan et al., submitted for publication),
which compares TNBC with Her2+ breast cancers. In this
study, keratin 19 was found expressed eightfold lower in
TNBC. Thus, change in cell stiffness may be a newly
described characteristic of cancer cells that affects the way
they spread and the molecules regulate this function.
Annexin family proteins were found over-expressed in
TNBC (Table 5), which is consistent with our previous
finding [14, 19] in TNBC tumors and cell lines. The protein
family of annexins has continued to grow since their
association with intracellular membranes was first reported
in 1977 [39]. Annexins are important in various cellular and
physiological functions such as providing a membrane
scaffold, which is relevant to changes in the cell's shape
[40, 41]. Also, annexins have been shown to be involved in
trafficking and organization of vesicles, exocytosis, endo-
cytosis, and calcium ion channel formation [42]. A
literature search indicates that Annexin over-expression
correlates with the aggressiveness of cancer. Annexin A3
was significantly up-regulated in invasive lung adenocarci-
nomas with lymph node metastasis compared to those
without lymph node metastasis [43]. Similarly, annexin A5
and A7 are significantly elevated in lymphatic metastasis of
mouse hepatocarcinoma [44]. Together, these findings
provide strong evidence that Annexin family proteins are
Table 7 Epithelial keratins detected in specimens of 10 TNBC and 10 ER+PR+Her2− (non-TNBC) breast cancer
Identified epithelial keratin
(new nomenclature)
Type Accession number Molecular weight (kDa) Ratio of non-TNBC/TNBC Average detected spectra
of TNBC ± SE
Keratin 1 (K1) II gi|1346343 66 2.5 16.3±4.0
Keratin 2 (K2) II gi|547754 66 2.0 3.3±1.1
Keratin 5 (K5) II gi|119395754 62 2.0 1.0±0.0
Keratin 7 (K7) II gi|20178293 51 3.3 1.6±1.2
Keratin 8 (K8) II gi|4504919 54 3.3 0.4±0.3
Keratin 9 (K9) I gi|81175178 62 10.0 1.1±1.1
Keratin 10(K10) I gi|147744568 60 5.0 6.7±2.0
Keratin 18 (K18) I gi|4557888 48 2.5 0.2±0.2
Keratin 19 (K19) I gi|90111766 44 3.3 2.3±1.3
Identified heat shock proteins Accession number Fold change of
TNBC/non-TNBC
Average detected
spectra of
TNBC ± SE
Heat shock 70 kDa protein 5 gi|16507237 2.9 54.4±18.2
Heat shock 90 kDa protein 1, beta gi|20149594 1.1 30.7±7.6
Heat shock 70 kDa protein 8 isoform 1 gi|5729877 1.4 24.7±8.8
Heat shock protein 90 kDa beta,
member 1
gi|4507677 3.3 30.1±8.9
Heat shock 70 kDa protein 9 precursor gi|24234688 1.8 8.6±3.8
Average fold=2.1
Table 8 Selected heat
shock proteins detected in
specimens of 10 TNBC and
10 ER+PR+Her2− (non-TNBC)
breast cancer cases
100 Clin Proteom (2010) 6:93–103likelytocontributetotheaggressivephenotype andmetastatic
potential of TNBC.
In this study, we also found an overall up-regulation of
heat shock protein expression in TNBC. Heat shock
proteins are a class of functionally related proteins whose
expression is transcriptionally regulated and over-expressed
when cells are exposed to elevated temperatures, hypoxia,
or other stress [45]. Heat shock proteins are named
according to their molecular weight. Among them, Hsp60,
Hsp70, and Hsp90 are the most widely studied Hsps. Hsps
have a dual function depending on their intracellular or
extracellular location. The different properties of Hsps allow
them to be exploited in therapy. Intracellular Hsps are
protective to the cell and are highly expressed in cancerous
cells. The elevated Hsp expression has been shown to
promote cancer growth through inhibition of programmed
cell death (Hsp27, Hsp70), allowance of autonomous tumor
growth (Hsp90) and tumor resistance to chemotherapy and
hyperthermia [46]. Since they participate in oncogenesis
and in resistance to treatment, the inhibition of Hsps has
been tested in clinical trial for cancer treatment. Small
molecule inhibitors of Hsps, especially Hsp90, show
promise as anticancer agents [35]. The potent Hsp90
inhibitor 17-AAG is currently in clinical trials for the
treatment of several types of cancer [47]. In contrast to the
intracellular Hsps, extracellularly located or membrane-
bound Hsps mediate immunological functions. They can
elicit an immune response modulated either by the adaptive
or innate immune system [35]. Their immunogenicity can
be used to form the basis of anticancer vaccines [46].
Our mass spectrometric results showed a significant
over-expression of Hsp70 and Hsp90 in the TNBC tumors.
Another parallel study comparing TNBC with Her2+
tumors in our laboratory indicates that Hsp70 and Hsp90
are over-expressed in TNBC (He et al., in preparation). This
is consistent with other studies reporting Hsp70 and Hsp90
expression associated with tumor of poor differentiation,
rapid proliferation, and suppressed apoptosis. Clinically,
they are associated with lymph node metastasis and poor
clinical outcome [48–50].
Among the nine unique proteins detected exclusively in
10 TNBC cases, two of them were HLA class proteins
(Table 3): HLA class II histocompatibility antigen DR alpha
and HLA class I histocompatibility antigen A-23 alpha
were both over-expressed in TNBC but below detection
level in ER+PR+Her2− breast cancer specimens. These two
proteins belong to the major histocompatibility complex
(MHC) class II and I family, respectively. They are
membrane proteins, which explain the reason they exist in
hydrophobic fractions.
The MHC is a large gene family, which is the most gene-
dense region of the mammalian genome and plays an
important role in the immune system and autoimmunity
[51]. The MHC proteins display both self antigens (peptide
fragments from the cell itself) and non-self antigens (e.g.,
fragments of invading microorganisms or cancer) to T cells
and NK cells. Under normal conditions, expression of MHC
molecules inhibitskillingbyNKcells,while absence ofMHC
molecules in infected or stressed cells allows cell-mediated
cytotoxicity to occur. MHC class I molecules express on all
nucleatedcells,whileMHCclassIIfamilyproteinsexpresson
most immune system cells, specifically on antigen-presenting
cells. Thus, over-expression of MHC class II and I proteins in
tumor tissue suggests two possibilities. First, antigens may
exist on tumor cell surfaces carrying different biological
functions to tumor cells. Second, TNBC may have more
lymphocytic infiltration, which may be the source of MHC
over-expression found in these tumors. Recent studies
reported that several HLA protein over-expression are
associated with breast cancer [52, 53] and may favor their
escape from anti-tumor immune responses [54], as well as
predict chemotherapy resistance [55].
The rapid development of analytical instruments and
data mining software in the last two decades has signifi-
cantly extended the possibilities of studying proteins in life
sciences. Proteomic analysis provides deeper insights into
qualitative and quantitative changes in protein composition
in association with the disease process. The combination of
hydrophobic fractionation and nano-LC mass spectrometry
analysis of cancer proteome offers a promising tool in the
discovery of potential cancer bio-signatures. When suffi-
ciently refined, this approach may prove useful for early
detection and better treatment of breast cancer.
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